regulatory
confidence high
sentiment negative
materiality 0.70
Karyopharm receives Nasdaq deficiency notice for bid price below $1.00
Karyopharm Therapeutics Inc.
- Stock closed below $1.00 for 32 consecutive business days, violating Bid Price Rule 5450(a)(1).
- Company has 180 days, until March 17, 2025, to regain compliance by closing at $1.00+ for 10 consecutive days.
- Failure to cure may allow a 180-day extension if stock moves to Nasdaq Capital Market and meets other listing standards.
- Company may consider a reverse stock split, but there is no assurance of regaining compliance.